AGN Allergan plc

128.16
+7.52  (+6%)
Previous Close 120.64
Open 122.91
Price To Book 0.68
Market Cap 42,011,092,145
Shares 327,801,905
Volume 6,974,089
Short Ratio 1.99
Av. Daily Volume 2,685,325

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval (third indication) announced October 3, 2017.
Botox
Forehead lines
Phase 2 data due 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Approval announced March 20, 2017.
JUVÉDERM VOLLURE
Correction of moderate to severe facial wrinkles and folds
Phase 3 data due 2020.
Brazikumab
Crohn's disease
Phase 3 enrollment to be completed 2H 2018.
Bimatoprost
Androgenic Alopecia
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Botox
Depression
Phase 2b trial ongoing.
RORγt agonist
Psoriasis
Approval announced November 13, 2017.
Cariprazine
Maintenance Treatment of Schizophrenia
Phase 3 data released January 24, 2019 - primary endpoint met.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3 trial to be initiated 1H 2019 with data due in 2020.
ATOGEPANT
Prophylaxis (migraine)
Phase 3 trials did not meet primary endpoints - March 6, 2019.
RAPASTINEL
Major depressive disorder (MDD)
Phase 3 top-line data due 2020.
RELAMORELIN
Diabetic Gastroparesis
CRL issued August 21, 2018.
ESMYA (ulipristal acetate)
Uterine Fibroids
Phase 3 trial to be initiated 2019.
ABICIPAR
Diabetic macular edema (DME)
Phase 3 data due 2020.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
BLA filing due 1H 2019.
ABICIPAR
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
FDA Approval announced May 28, 2019.
Cariprazine
Bipolar I Depression
NDA acceptance announced March 11, 2019. PDUFA 4Q 2019. No exact date provided.
UBROGEPANT
Migraine
Phase 2/3 data due 2020.
Brazikumab
Ulcerative colitis
Phase 3 trial to be initiated 2H 2018.
Brimo DDS
Geographic atrophy
NDA filing due 1H 2019.
Bimatoprost
Open-angle glaucoma or ocular hypertension
FDA Approval announced March 18, 2019.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI) - pediatric
PDUFA date 4Q 2019.
Botox
Lower limb spasticity
PDUFA date under priority review 2Q 2019. Exact date not provided.
Botox
Upper limb spasticity
Phase 2 top-line data due 2H 2019.
AGN-241751
Major Depressive Disorder (MDD)
Phase 3 top-line data due 2020.
Presbysol
Presbyopia
Phase 2 monotherapy interim analysis 2H 2019.
RAPASTINEL
Depression

Latest News

  1. What’s Pulling Down Allergan’s Share Price in 2019?
  2. Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients
  3. US STOCKS-Stocks approach record as Fed soothes Wall Street's fears
  4. How Are Allergan’s Margins and Expenses Trending in 2019?
  5. US STOCKS-Wall Street climbs after Fed signals potential rate cuts
  6. Allergan Stock Is Moving Up on Expectations of a Breakup
  7. Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
  8. US STOCKS-Wall Street pauses with Fed meeting in focus
  9. Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective
  10. Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
  11. Allergan stock jumps 3.8% after Evercore ISI analyst says company is likely heading toward a split
  12. Migraine-Drug Deal Hype Turns Into a Giant Headache
  13. 3 Big Stock Charts for Monday: Centurylink, Allergan and Charles Schwab
  14. Allergan plc's (NYSE:AGN) Profit Outlook
  15. Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti
  16. Pharmaceutical giant Allergan expands in Northwest Austin
  17. Short Sellers Are Making Bigger Bets Against Teva and Allergan Stock
  18. Barclays Has New Plays for Healthcare Fans
  19. See what the IHS Markit Score report has to say about Allergan plc.
  20. Is Allergan plc (AGN) A Good Stock To Buy ?